Non-Segmental VitiligoPhase 1/2NCT07828639
A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo
A Phase 1/2 study testing VC005 tablets in people with Non-Segmental Vitiligo, run by Jiangsu vcare pharmaceutical technology co., LTD at 1 site in China.
Trial summary
This study is a multicenter, open-label, non-randomized study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with Non-Segmental Vitiligo Read more about this study
- Who is it for?
- Ages 12 to 18 years
- Conditions the study is for
- Non-Segmental Vitiligo
- What is being tested?
- VC005 tablets
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteChina
- Study dates
- 25 Sep 2026to 30 May 2027
- Phase
- Phase 1/2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- The subject fully understands this study and is able to comply with the relevant trial procedures. The subject and their legal guardian voluntarily sign the informed consent form (ICF).
- Age 12 to 18 years inclusive (including 12 years old, excluding 18 years old) at the time of signing the ICF, both genders, with body weight ≥ 30 kg.
- Subjects with a clinical diagnosis of non-segmental vitiligo
Who cannot join
- Pregnant or breastfeeding women, or subjects planning to become pregnant or breastfeed during the study period.
- Trial participants with complete depigmentation of hair within the vitiligo area.
- Trial participants clinically diagnosed with segmental vitiligo, mucosal non-segmental vitiligo, or other cutaneous depigmentation disorders.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
The Peking University People's Hospital
Beijing, Beijing Municipality
Jianzhong Zhang, 010-88325471, rmzjz@126.com
About this study
Official title: A Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo
This study is a multicenter, open-label, non-randomized study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with Non-Segmental Vitiligo
- Conditions
- Non-Segmental Vitiligo
- Being tested
- VC005 tablets
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VC005 tabletsDrug
VC005 repeat administration for up to 24 weeks
| Study group | Role | What they receive |
|---|---|---|
| VC005 Tablets | Experimental | Not described Receives: Drug: VC005 tablets |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC）
Measured: Day1，Day28
Peak Plasma Concentration (Cmax）
Measured: Day1，Day28
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2026
- Study start25 Sep 2026 (estimated)
- Primary completion30 May 2027 (estimated)
- Study completion30 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-Segmental VitiligoStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Jianzhong Zhang Zhang, Principal investigator, The Peking University People's Hospitalcheng zhou, Principal investigator, The Peking University People's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07828639
- Sponsor's protocol ID
- VC005-113
- Status last verified
- Sep 2026
- First submitted
- 15 Sep 2026
- Last updated
- 18 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No